Sirtris Pharmaceuticals, a biopharmaceutical company developing drugs to treat age-related diseases, priced 6 million shares, 20% more than the 5 million originally planned, at $10 per share, the midpoint of the $9-$11 price range, Tuesday evening. JPMorgan and CIBC were the bookrunners on the deal. The stock is expected to begin trading on the NASDAQ under the ticker "SIRT" on Wednesday.
